Trials / Completed
CompletedNCT00233571
A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis
A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 796 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in patients with rheumatoid arthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab 40 mg subcutaneous (SC) every other week (EOW) |
Timeline
- Start date
- 2000-06-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-10-06
- Last updated
- 2011-11-22
Source: ClinicalTrials.gov record NCT00233571. Inclusion in this directory is not an endorsement.